Industry News
Biotechnology Industry News

MD Anderson inks deal to put Chinese cancer drugs through trials, starting with a PI3K inhibitor
MD Anderson inks deal to put Chinese cancer drugs through trials, starting with a PI3K inhibitor ntaylor Fri, 01/21/2022 - 08:00
Kura exits FDA clinical hold after agreeing to mitigation measures, enabling resumption of blood cancer trial
Kura exits FDA clinical hold after agreeing to mitigation measures, enabling resumption of blood cancer trial ntaylor Fri, 01/21/2022 - 06:37
CROs embracing tech to decentralize trials and speed enrollment as regulators show support ‘with their feet’
CROs embracing tech to decentralize trials and speed enrollment as regulators show support 'with their feet' aarmstrong Thu, 01/20/2022 - 08:54
Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinic
Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinic ntaylor Thu, 01/20/2022 - 08:18
Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount
Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount ntaylor Thu, 01/20/2022 - 05:27
Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen’s Aduhelm
Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm aarmstrong Wed, 01/19/2022 - 13:56
Fierce JPM Week: As Novartis tries to avoid ‘me-too’ meds in M&A hunt, R&D chief urges biotechs to ‘please reach out’
Fierce JPM Week: As Novartis tries to avoid 'me-too' meds in M&A hunt, R&D chief urges biotechs to 'please reach out' aarmstrong Wed, 01/19/2022 - 12:59
Charles River diving deeper into AI drug development in partnership with Valo Health
Charles River diving deeper into AI drug development in partnership with Valo Health jkeenan Wed, 01/19/2022 - 10:09
Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease
Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease ntaylor Wed, 01/19/2022 - 06:36
Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began
Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began ntaylor Wed, 01/19/2022 - 05:42
Eli Lilly lines up metabolic pacts with Evotec, Abbisko as it awaits diabetes med nod from FDA
Eli Lilly lines up metabolic pacts with Evotec, Abbisko as it awaits diabetes med nod from FDA klahucik Tue, 01/18/2022 - 09:07
With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapy
With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapy ntaylor Tue, 01/18/2022 - 08:26
Fierce JPM Week: Johnson & Johnson’s JLABS—Taming the beast, while letting it roam the world
Fierce JPM Week: Johnson & Johnson's JLABS—Taming the beast, while letting it roam the world badams Tue, 01/18/2022 - 07:38
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington’s trial
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial ntaylor Tue, 01/18/2022 - 05:37
‘Shots on goal’ to ‘deterministic’ drug development: Flagship CEO, Moderna Chair Noubar Afeyan pens first annual letter
'Shots on goal' to 'deterministic' drug development: Flagship CEO, Moderna Chair Noubar Afeyan pens first annual letter klahucik Fri, 01/14/2022 - 10:33
‘Shots on goal’ to ‘deterministic’ drug development: Flagship CEO, Moderna Chair Afeyan pens first annual letter
'Shots on goal' to 'deterministic' drug development: Flagship CEO, Moderna Chair Afeyan pens first annual letter klahucik Fri, 01/14/2022 - 10:33
JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO space
JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO space aarmstrong Fri, 01/14/2022 - 09:49
FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish
FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish ntaylor Fri, 01/14/2022 - 07:04
EMA sets out plan to accelerate clinical trials, reduce administrative burden
EMA sets out plan to accelerate clinical trials, reduce administrative burden ntaylor Fri, 01/14/2022 - 05:47
FDA denies Denali’s Takeda-partnered Alzheimer’s drug from entering clinic
FDA denies Denali's Takeda-partnered Alzheimer's drug from entering clinic klahucik Thu, 01/13/2022 - 09:04

